NCT04612907 Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
| NCT ID | NCT04612907 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Umeå University |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 420 participants |
| Start Date | 2022-10-31 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 420 participants in total. It began in 2022-10-31 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
Eligibility Criteria
Inclusion Criteria: 1. Signed Informed Consent 2. Histological confirmed prostate cancer 3. Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number of lymph nodes 4. baseline E-PROM Exclusion Criteria: 1. High burden metastatic prostate cancer including all with visceral mets. 2. Unable to comply with study procedures. 3. Other diseases or medication that will put the patient at risk for more toxicity from radiotherapy 4. Radiation treatment start later than nine months after the prostate cancer diagnosis. 5. Severe micturition problems, IPSS \> 20 ( International Prostate Symptom Score)
Contact & Investigator
Camilla of T Karlsson
PRINCIPAL INVESTIGATOR
Cancercentrum Umeå University
Frequently Asked Questions
Who can join the NCT04612907 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04612907 currently recruiting?
Yes, NCT04612907 is actively recruiting participants. Contact the research team at camilla.thellenberg@umu.se for enrollment information.
Where is the NCT04612907 trial being conducted?
This trial is being conducted at Umeå, Sweden.
Who is sponsoring the NCT04612907 clinical trial?
NCT04612907 is sponsored by Umeå University. The principal investigator is Camilla of T Karlsson at Cancercentrum Umeå University. The trial plans to enroll 420 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.